Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML.
Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Horrigan S, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KN.
Saenz DT, et al. Among authors: sun b.
Leukemia. 2019 Jun;33(6):1373-1386. doi: 10.1038/s41375-018-0334-3. Epub 2018 Dec 21.
Leukemia. 2019.
PMID: 30575820